| Year |
Citation |
Score |
| 2020 |
Goodman KE, Pineles L, Magder LS, Anderson DJ, Ashley ED, Polk RE, Quan H, Trick WE, Woeltje KF, Leekha S, Cosgrove SE, Harris AD. Electronically Available Patient Claims Data Improve Models for Comparing Antibiotic Use Across Hospitals: Results from 576 U.S. Facilities. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32756970 DOI: 10.1093/Cid/Ciaa1127 |
0.389 |
|
| 2020 |
Goodman KE, Cosgrove SE, Pineles L, Magder LS, Anderson DJ, Dodds Ashley E, Polk RE, Quan H, Trick WE, Woeltje KF, Leekha S, Harris AD. Significant Regional Differences in Antibiotic Use Across 576 U.S. Hospitals and 11,701,326 Million Adult Admissions, 2016 - 2017. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32421195 DOI: 10.1093/Cid/Ciaa570 |
0.384 |
|
| 2014 |
Ibrahim OM, Polk RE. Antimicrobial use metrics and benchmarking to improve stewardship outcomes: methodology, opportunities, and challenges. Infectious Disease Clinics of North America. 28: 195-214. PMID 24857388 DOI: 10.1016/J.Idc.2014.01.006 |
0.613 |
|
| 2012 |
Harpe SE, Inocencio TJ, Pakyz AL, Oinonen MJ, Polk RE. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship. Pharmacotherapy. 32: 744-54. PMID 23307522 DOI: 10.1002/J.1875-9114.2012.01160.X |
0.37 |
|
| 2012 |
Schulz LT, Fox BC, Polk RE. Can the antibiogram be used to assess microbiologic outcomes after antimicrobial stewardship interventions? A critical review of the literature. Pharmacotherapy. 32: 668-76. PMID 23307516 DOI: 10.1002/J.1875-9114.2012.01163.X |
0.406 |
|
| 2012 |
Ababneh M, Harpe S, Oinonen M, Polk RE. Trends in aminoglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: Implications for antimicrobial stewardship Infection Control and Hospital Epidemiology. 33: 594-601. PMID 22561715 DOI: 10.1086/665724 |
0.41 |
|
| 2012 |
Ibrahim OM, Polk RE. Benchmarking antimicrobial drug use in hospitals. Expert Review of Anti-Infective Therapy. 10: 445-57. PMID 22512754 DOI: 10.1586/Eri.12.18 |
0.64 |
|
| 2012 |
Xu R, Polk RE, Stencel L, Lowe DK, Guharoy R, Duggal RW, Wiest M, Putney KS, Flint NB. Antibiogram compliance in University HealthSystem Consortium participating hospitals with Clinical and Laboratory Standards Institute guidelines. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 69: 598-606. PMID 22441793 DOI: 10.2146/Ajhp110332 |
0.307 |
|
| 2012 |
Pakyz AL, Lee JA, Ababneh MA, Harpe SE, Oinonen MJ, Polk RE. Fluoroquinolone use and fluoroquinolone-resistant Pseudomonas aeruginosa is declining in US academic medical centre hospitals. The Journal of Antimicrobial Chemotherapy. 67: 1562-4. PMID 22416053 DOI: 10.1093/Jac/Dks083 |
0.434 |
|
| 2011 |
Polk RE, Hohmann SF, Medvedev S, Ibrahim O. Benchmarking risk-adjusted adult antibacterial drug use in 70 US academic medical center hospitals Clinical Infectious Diseases. 53: 1100-1110. PMID 21998281 DOI: 10.1093/Cid/Cir672 |
0.639 |
|
| 2010 |
Pakyz AL, Carroll NV, Harpe SE, Oinonen M, Polk RE. Increase in use of vancomycin for Clostridium difficile infection in US hospitals. Infection Control and Hospital Epidemiology. 31: 867-8. PMID 20586649 DOI: 10.1086/655442 |
0.354 |
|
| 2009 |
Pakyz AL, Gurgle HE, Ibrahim OM, Oinonen MJ, Polk RE. Trends in antibacterial use in hospitalized pediatric patients in United States academic health centers. Infection Control and Hospital Epidemiology. 30: 600-3. PMID 19419328 DOI: 10.1086/597545 |
0.599 |
|
| 2009 |
Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 53: 1983-6. PMID 19273670 DOI: 10.1128/Aac.01535-08 |
0.424 |
|
| 2008 |
Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in US academic health centers: 2002 to 2006. Archives of Internal Medicine. 168: 2254-60. PMID 19001203 DOI: 10.1001/Archinte.168.20.2254 |
0.399 |
|
| 2008 |
Pakyz A, Powell JP, Harpe SE, Johnson C, Edmond M, Polk RE. Diversity of antimicrobial use and resistance in 42 hospitals in the United States. Pharmacotherapy. 28: 906-12. PMID 18576905 DOI: 10.1592/Phco.28.7.906 |
0.376 |
|
| 2008 |
MacDougall C, Polk RE. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infection Control and Hospital Epidemiology. 29: 203-11. PMID 18257689 DOI: 10.1086/528810 |
0.308 |
|
| 2007 |
Lautenbach E, Polk RE. Resistant gram-negative bacilli: A neglected healthcare crisis? American Journal of Health-System Pharmacy. 64. PMID 18029939 DOI: 10.2146/Ajhp070477 |
0.386 |
|
| 2007 |
Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 44: 664-70. PMID 17278056 DOI: 10.1086/511640 |
0.414 |
|
| 2005 |
MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clinical Microbiology Reviews. 18: 638-56. PMID 16223951 DOI: 10.1128/Cmr.18.4.638-656.2005 |
0.39 |
|
| 2005 |
MacDougall C, Harpe SE, Powell JP, Johnson CK, Edmond MB, Polk RE. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerging Infectious Diseases. 11: 1197-204. PMID 16102307 DOI: 10.3201/Eid1108.050116 |
0.409 |
|
| 2005 |
MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 41: 435-40. PMID 16028149 DOI: 10.1086/432056 |
0.372 |
|
| 2004 |
Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 39: 497-503. PMID 15356812 DOI: 10.1086/422647 |
0.384 |
|
| 2004 |
Cook PP, Catrou PG, Christie JD, Young PD, Polk RE. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. The Journal of Antimicrobial Chemotherapy. 53: 853-9. PMID 15044426 DOI: 10.1093/Jac/Dkh163 |
0.369 |
|
| 2003 |
Polk RE. Antimicrobial formularies: can they minimize antimicrobial resistance? American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 60: S16-9. PMID 12789883 DOI: 10.1093/Ajhp/60.Suppl_1.S16 |
0.397 |
|
| 2001 |
Sadler BM, Chittick GE, Polk RE, Slain D, Kerkering TM, Studenberg SD, Lou Y, Moore KHP, Woolley JL, Stein DS. Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects Journal of Clinical Pharmacology. 41: 386-396. PMID 11304895 DOI: 10.1177/00912700122010249 |
0.316 |
|
| 2001 |
Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Lou Y, Kristoff D, Stein DS. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males Antimicrobial Agents and Chemotherapy. 45: 502-508. PMID 11158747 DOI: 10.1128/Aac.45.2.502-508.2001 |
0.324 |
|
| 2000 |
Monroe S, Polk R. Antimicrobial use and bacterial resistance. Current Opinion in Microbiology. 3: 496-501. PMID 11050449 DOI: 10.1016/S1369-5274(00)00129-6 |
0.384 |
|
| 2000 |
Brophy DF, Israel DS, Pastor A, Gillotin C, Chittick GE, Symonds WT, Lou Y, Sadler BM, Polk RE. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers Antimicrobial Agents and Chemotherapy. 44: 978-984. PMID 10722500 DOI: 10.1128/Aac.44.4.978-984.2000 |
0.364 |
|
| 1999 |
Polk RE, Crouch MA, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WT, Gouldin W, Lou Y. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men Pharmacotherapy. 19: 1378-1384. PMID 10600086 DOI: 10.1592/Phco.19.18.1378.30905 |
0.367 |
|
| 1999 |
McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. Pharmacokinetics of [14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: A mass balance study Antimicrobial Agents and Chemotherapy. 43: 2855-2861. PMID 10582871 DOI: 10.1128/Aac.43.12.2855 |
0.314 |
|
| 1999 |
Polk R. Optimal Use of Modern Antibiotics: Emerging Trends Clinical Infectious Diseases. 29: 264-274. PMID 10476723 DOI: 10.1086/520196 |
0.39 |
|
| 1997 |
Watkins VS, Polk RE, Stotka JL. Drug interactions of macrolides: Emphasis on dirithromycin Annals of Pharmacotherapy. 31: 349-356. PMID 9066944 DOI: 10.1177/106002809703100314 |
0.318 |
|
| 1996 |
Gillum JG, Sesler JM, Bruzzese VL, Israel DS, Polk RE. Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers Antimicrobial Agents and Chemotherapy. 40: 1866-1869. PMID 8843295 DOI: 10.1128/Aac.40.8.1866 |
0.343 |
|
| 1996 |
Israel DS, Stotka J, Rock W, Sintek CD, Kamada AK, Klein C, Swaim WR, Pluhar RE, Toscano JP, Lettieri JT, Heller AH, Polk RE. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 22: 251-6. PMID 8838180 DOI: 10.1093/Clinids/22.2.251 |
0.327 |
|
| 1996 |
Gillum JG, Israel DS, Scott RB, Climo MW, Polk RE. Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. Antimicrobial Agents and Chemotherapy. 40: 1715-6. PMID 8807068 DOI: 10.1128/Aac.40.7.1715 |
0.32 |
|
| 1996 |
Polk R. Vancomycin prescribing in the era of vancomycin-resistant enterococci. Pharmacotherapy. 15: 682-3. PMID 8570444 DOI: 10.1002/J.1875-9114.1995.Tb02881.X |
0.325 |
|
| 1995 |
Bruzzese VL, Gillum JG, Israel DS, Johnson GL, Kaplowitz LG, Polk RE. Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus Antimicrobial Agents and Chemotherapy. 39: 1050-1053. PMID 7625787 DOI: 10.1128/Aac.39.5.1050 |
0.36 |
|
| 1993 |
Israel D, Gillum JG, Turik M, Harvey K, Ford J, Dalton H, Towle M, Echols R, Heller AH, Polk R. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrobial Agents and Chemotherapy. 37: 2193-2199. PMID 8257144 DOI: 10.1128/Aac.37.10.2193 |
0.358 |
|
| 1993 |
Polk RE, Israel D, Wang J, Venitz J, Miller J, Stotka J. Vancomycin skin tests and prediction of 'red man syndrome' in healthy volunteers Antimicrobial Agents and Chemotherapy. 37: 2139-2143. PMID 8257136 DOI: 10.1128/Aac.37.10.2139 |
0.304 |
|
| 1993 |
Gillum JG, Israel DS, Polk RE. Pharmacokinetic Drug Interactions with Antimicrobial Agents Clinical Pharmacokinetics. 25: 450-482. PMID 8119047 DOI: 10.2165/00003088-199325060-00005 |
0.317 |
|
| 1991 |
Healy DP, Schoenle JR, Stotka J, Polk RE. Lack of interaction between lomefloxacin and caffeine in normal volunteers Antimicrobial Agents and Chemotherapy. 35: 660-664. PMID 2069371 DOI: 10.1128/Aac.35.4.660 |
0.335 |
|
| 1991 |
Polk RE. Anaphylactoid reactions to glycopeptide antibiotics Journal of Antimicrobial Chemotherapy. 27: 17-29. PMID 1711520 DOI: 10.1093/Jac/27.Suppl_B.17 |
0.305 |
|
| 1990 |
Sahai J, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk R. Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome". Antimicrobial Agents and Chemotherapy. 34: 765-9. PMID 1694421 DOI: 10.1128/Aac.34.5.765 |
0.36 |
|
| 1990 |
Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and 'red man syndrome': Comparison of 1- and 2-hour infusions Antimicrobial Agents and Chemotherapy. 34: 550-554. PMID 1693055 DOI: 10.1128/Aac.34.4.550 |
0.312 |
|
| 1989 |
Healy DP, Polk RE, Kanawati L, Rock DT, Mooney ML. Interaction between oral ciprofloxacin and caffeine in normal volunteers Antimicrobial Agents and Chemotherapy. 33: 474-478. PMID 2729942 DOI: 10.1128/Aac.33.4.474 |
0.332 |
|
| 1989 |
Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones The American Journal of Medicine. 87. PMID 2686430 DOI: 10.1016/0002-9343(89)90028-4 |
0.316 |
|
| 1989 |
Polk RE, Healy DP, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers Antimicrobial Agents and Chemotherapy. 33: 1841-1844. PMID 2610494 DOI: 10.1128/Aac.33.11.1841 |
0.342 |
|
| 1989 |
Sahal J, Healy DP, Garris R, Berry A, Polk RE. Influence of Antihistamine Pretreatment on Vancomycin-Induced Red-Man Syndrome Journal of Infectious Diseases. 160: 876-881. PMID 2572652 DOI: 10.1093/Infdis/160.5.876 |
0.308 |
|
| 1988 |
Polk RE, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. The Journal of Infectious Diseases. 157: 502-7. PMID 2449506 DOI: 10.1093/Infdis/157.3.502 |
0.323 |
|
| 1987 |
Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrobial Agents and Chemotherapy. 31: 393-7. PMID 3579256 DOI: 10.1128/Aac.31.3.393 |
0.322 |
|
| 1986 |
Harford AM, Sica DA, Tartaglione T, Polk RE, Dalton HP, Poynor W. Vancomycin pharmacokinetics in continuous ambulatory peritoneal dialysis patients with peritonitis Nephron. 43: 217-222. PMID 3724930 DOI: 10.1159/000183833 |
0.382 |
|
| 1986 |
Polk RE, Hepler CD. Controversies in antimicrobial therapy: Critical analysis of clinical trials American Journal of Hospital Pharmacy. 43: 630-640. PMID 3706318 DOI: 10.1093/Ajhp/43.3.630 |
0.328 |
|
| 1986 |
Sica DA, Polk RE, Kerkering TM, Patterson P, Baggett J. Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis European Journal of Clinical Pharmacology. 30: 713-717. PMID 3464435 DOI: 10.1007/Bf00608221 |
0.324 |
|
| 1985 |
Tartaglione TA, Polk RE. Review of the new second-generation cephalosporins: Cefonicid, ceforanide, and cefuroxime Drug Intelligence and Clinical Pharmacy. 19: 188-198. PMID 3884304 DOI: 10.1177/106002808501900304 |
0.347 |
|
| 1983 |
Polk RE, Mayhall CG, Smith J, Hall G, Kline BJ, Swensson E, Haynes BW. Gentamicin and Tobramycin Penetration Into Burn Eschar: Pharmacokinetics and Microbiological Effects Archives of Surgery. 118: 295-302. PMID 6824430 DOI: 10.1001/Archsurg.1983.01390030027005 |
0.394 |
|
| 1983 |
Hume AL, Polk R, Kline B, Cardea J. Comparative penetration of latamoxef (moxalactam) and cefazolin into human knee following simultaneous administration Journal of Antimicrobial Chemotherapy. 12: 623-627. PMID 6662840 DOI: 10.1093/Jac/12.6.623 |
0.33 |
|
| 1983 |
Mayhall CG, Polk RE, Haynes BW. Infections in burned patients Infection Control. 4: 454-459. PMID 6418679 DOI: 10.1017/S019594170005846X |
0.306 |
|
| 1982 |
Polk RE, Smith JE, Ducey K, Lower RR. Penetration of moxalactam and cefazolin into atrial appendage after simultaneous intramuscular or intravenous administration Antimicrobial Agents and Chemotherapy. 22: 201-203. PMID 6927281 DOI: 10.1128/Aac.22.2.201 |
0.334 |
|
| 1982 |
Polk RE. Moxalactam (Moxam, Eli Lilly) Drug Intelligence and Clinical Pharmacy. 16: 104-112. PMID 6210519 DOI: 10.1177/106002808201600203 |
0.356 |
|
| 1981 |
Polk RE, Espinel-Ingroff A, Lockridge R. In vitro evaluation of a vancomycin radioimmunoassay and observations on vancomycin pharmacokinetics in dialysis patients Drug Intelligence and Clinical Pharmacy. 15: 15-20. PMID 7274010 DOI: 10.1177/106002808101500103 |
0.343 |
|
| 1981 |
Polk RE, Kline BJ, Markowitz SM. Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion Antimicrobial Agents and Chemotherapy. 20: 576-579. PMID 6459759 DOI: 10.1128/Aac.20.5.576 |
0.352 |
|
| 1981 |
Henderson JL, Polk RE, Kline BJ. In vitro inactivation of gentamicin, tobramycin, and netilmicin by carbenicillin, azlocillin, or mezlocillin. American Journal of Hospital Pharmacy. 38: 1167-70. PMID 6455916 DOI: 10.1093/Ajhp/38.8.1167 |
0.303 |
|
| 1981 |
Polk RE, Stephens GH. Effects of cefazolin and moxalactam on serum chemistry values determined by autoanalyzer American Journal of Hospital Pharmacy. 38: 866-868. PMID 6454343 DOI: 10.1093/Ajhp/38.6.866 |
0.314 |
|
| 1978 |
Polk RE, Archer GL, Lower R. Cefamandole kinetics during cardiopulmonary bypass Clinical Pharmacology and Therapeutics. 23: 473-480. PMID 630796 DOI: 10.1002/Cpt1978234473 |
0.315 |
|
| 1978 |
Archer GL, Polk RE, Duma RJ, Lower R. Comparison of cephalothin and cefamandole prophylaxis during insertion of prosthetic heart valves Antimicrobial Agents and Chemotherapy. 13: 924-929. PMID 354521 DOI: 10.1128/Aac.13.6.924 |
0.332 |
|
| Show low-probability matches. |